Heterogeneity in adverse events related to Atezolizumab-Bevacizumab for hepatocellular carcinoma reported in real-life studies-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Heterogeneity in adverse events related to Atezolizumab-Bevacizumab for hepatocellular carcinoma reported in real-life studies

Published:2024-08 Issue: Volume: Page:101190
ISSN:2589-5559
Container-title:JHEP Reports
language:en
Short-container-title:JHEP Reports

Author:

Campani Claudia^ORCID,Pallas Dimitrios^ORCID,Sidali Sabrina^ORCID,Giouleme Olga,Blaise Lorraine,Grando Véronique,Nkontchou Gisele,Demory Alix,Nahon Pierre^ORCID,Ganne-Carrié Nathalie^ORCID,Nault Jean-Charles^ORCID

Publisher

Elsevier BV

Reference52 articles.

1. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update;Reig;Journal of Hepatology,2022

2. Hepatocellular carcinoma;Llovet;Nat Rev Dis Primers,2021

3. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma;Finn;N Engl J Med,2020

4. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma;Cheng;Journal of Hepatology,2022

5. Safety and Efficacy of Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma and Impaired Liver Function: A Systematic Review and Meta-Analysis;Pasta;Liver Cancer,2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP